Entries by cticadmin

Goldman-Backed Heart Valve Startup Is Said to Mull Hong Kong IPO

(Bloomberg) — Venus MedTech, a Chinese developer of heart valve replacements backed by Goldman Sachs Group Inc., is considering a Hong Kong initial public offering, people with knowledge of the matter said. Venus, based in the eastern Chinese city of Hangzhou, is weighing a plan to sell shares as soon as early next year, according […]

Chinese investors bet $100 million on Stealth Bio’s mitochondria tech

Independent mitochondrial DNA specialist Stealth BioTherapeutics has raised $100 million from Nan Fung Technology’s Pivotal Beta and other new and existing investors. Chief executive Reenie McCarthy said: “We particularly welcome our new investors’ deep experience within the China healthcare market, which we view as an important frontier both for rare mitochondrial diseases under China’s recent […]

C-Bridge Capital Leads Series B Round In Chinese Pharmaceutical Firm Nuance Biotech

Nuance Biotech, a China-based specialty pharmaceutical company, today announced series B fundraising of US$20 million with additional capital US$15 million tied to its acquisition of new products, led by C-Bridge Capital, a private equity firm focused on Chinese healthcare market. Shanghai-based Nuance Biotech was co-founded by Shao Yibo, a managing partner at Matrix Partners China […]

Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China

CAMBRIDGE, Mass. and SUZHOU, China, June 4, 2018 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, and CStone Pharmaceuticals, a privately-held biopharmaceutical company devoted to developing a new generation of innovative drugs, today announced an exclusive collaboration and license agreement for the development and commercialization of avapritinib, […]

Chinese fund invests in British surgical robot

By Angus McNeice | chinadaily.com.cn | Updated: 2018-06-06 01:05 A British company that has developed a robot that performs surgery has raised $100 million in funding from five investors including the Zhejiang SilkRoad Fund in China. Cambridge-based CMR Surgical has created the world’s smallest surgical robot, called Versius, that performs laparoscopy, or “keyhole” surgery, with […]

Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics for Inflammatory Indications

SHANGHAI, China and CAMBRIDGE, United Kingdom, May 30, 2018 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, and Crescendo Biologics Ltd (Crescendo Biologics), the developer of multi-functional biologics, announced today an exclusive, worldwide licensing agreement under which Zai Lab will develop, commercialize, and manufacture a topical, innovative antibody VH domain therapeutic […]

China’s CDH Investments said to raise $1b for fifth mezzanine fund

Ardi Wirdana, May 14, 2018 Chinese fund manager CDH Investments has raised a sum of $1 billion for its China-focused fifth mezzanine fund, according to a report by Private Debt Investor. The first close of the fund came late last year at $484 million, with backers including insurance companies, banks, trust companies and other institutional […]

Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic Development Collaboration for ETX2514

WALTHAM, Mass. and SHANGHAI, China, April 25, 2018 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, and Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced an exclusive license agreement for ETX2514 in the Asia-Pacific region and a global strategic […]

Tocagen Licenses Greater China Rights for Phase III Cancer Immunotherapy to ApolloBio

Tocagen has granted ApolloBio exclusive rights to its Phase III two-part cancer immunotherapy candidate Toca 511 (vocimagene amiretrorepvec) and Toca FC in the greater China region, in a deal that could generate up to $127 million-plus for Tocagen. Under the companies’ license agreement, ApolloBio has agreed to develop and commercialize biologic Toca 511 and small-molecule […]